David Hsiehchen

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 14

Top Topics

Advanced Non Small Cell Lung Cancer

Prognostic Factors

Clinical Evaluation

Circulating Tumor

Top Venues

Nature communications

Cancer research communications

This page only lists publications with an associated author ORCID identifier.

Publications

David Hsiehchen, Muhammad S Beg, Radhika Kainthla, Jay Lohrey, Syed M Kazmi, Leticia Khosama, Mary Claire Maxwell, Heather Kline, Courtney Katz, Asim Hassan, Naoto Kubota, Ellen Siglinsky, Anil K Pillai, Hagop Youssoufian, Colleen Mockbee, Kerry Culm, Mark Uhlik, Laura Benjamin, Rolf A Brekken, Chul Ahn, Amit G Singal, Hao Zhu, Yujin Hoshida, Adam C Yopp
The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trial. Nature communications 15 (1) (2024)
David Hsiehchen, Muhammad S Beg, Radhika Kainthla, Jay Lohrey, Syed M Kazmi, Leticia Khosama, Mary Claire Maxwell, Heather Kline, Courtney Katz, Asim Hassan, Naoto Kubota, Ellen Siglinsky, Anil K Pillai, Hagop Youssoufian, Colleen Mockbee, Kerry Culm, Mark Uhlik, Laura Benjamin, Rolf A Brekken, Chul Ahn, Amit G Singal, Hao Zhu, Yujin Hoshida, Adam C Yopp
The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trial. Nature communications 15 (1) (2024)
David Hsiehchen, Muhammad S Beg, Radhika Kainthla, Jay Lohrey, Syed M Kazmi, Leticia Khosama, Mary Claire Maxwell, Heather Kline, Courtney Katz, Asim Hassan, Naoto Kubota, Ellen Siglinsky, Anil K Pillai, Hagop Youssoufian, Colleen Mockbee, Kerry Culm, Mark Uhlik, Laura Benjamin, Rolf A Brekken, Chul Ahn, Amit G Singal, Hao Zhu, Yujin Hoshida, Adam C Yopp
The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trial. Nature communications 15 (1) (2024)
Maishara Muquith, Magdalena Espinoza, Andrew Elliott, Joanne Xiu, Andreas Seeber, Wafik S El-Deiry, Emmanuel S Antonarakis, Stephanie L Graff, Michael J Hall, Hossein Borghaei, Dave S B Hoon, Stephen V Liu, Patrick C Ma, Rana R McKay, Trisha Wise-Draper, John Marshall, George W Sledge, David Spetzler, Hao Zhu, David Hsiehchen
Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers. Nature cancer 5 (7) (2024)
David Hsiehchen, Muhammad S Beg, Radhika Kainthla, Jay Lohrey, Syed M Kazmi, Leticia Khosama, Mary Claire Maxwell, Heather Kline, Courtney Katz, Asim Hassan, Naoto Kubota, Ellen Siglinsky, Anil K Pillai, Hagop Youssoufian, Colleen Mockbee, Kerry Culm, Mark Uhlik, Laura Benjamin, Rolf A Brekken, Chul Ahn, Amit G Singal, Hao Zhu, Yujin Hoshida, Adam C Yopp
The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trial. Nature communications 15 (1) (2024)
Maishara Muquith, Magdalena Espinoza, Andrew Elliott, Joanne Xiu, Andreas Seeber, Wafik S El-Deiry, Emmanuel S Antonarakis, Stephanie L Graff, Michael J Hall, Hossein Borghaei, Dave S B Hoon, Stephen V Liu, Patrick C Ma, Rana R McKay, Trisha Wise-Draper, John Marshall, George W Sledge, David Spetzler, Hao Zhu, David Hsiehchen
Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers. Nature cancer (2024)
David Hsiehchen, Muhammad S Beg, Radhika Kainthla, Jay Lohrey, Syed M Kazmi, Leticia Khosama, Mary Claire Maxwell, Heather Kline, Courtney Katz, Asim Hassan, Naoto Kubota, Ellen Siglinsky, Anil K Pillai, Hagop Youssoufian, Colleen Mockbee, Kerry Culm, Mark Uhlik, Laura Benjamin, Rolf A Brekken, Chul Ahn, Amit G Singal, Hao Zhu, Yujin Hoshida, Adam C Yopp
The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trial. Nature communications 15 (1) (2024)
David Hsiehchen, Leslie Bucheit, Dong Yang, Muhammad Shaalan Beg, Mir Lim, Sunyoung S Lee, Pashtoon Murtaza Kasi, Ahmed O Kaseb, Hao Zhu
Author Correction: Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers. Nature communications 14 (1) (2023)
Arathi Mohan, Kent A Griffith, Fulei Wuchu, David B Zhen, Chandan Kumar-Sinha, Oxana V Crysler, David Hsiehchen, Thomas Enzler, Dominique Dippman, Valerie Gunchick, Abhinav Achreja, Olamide Animasahun, Srinadh Choppara, Minal Nenwani, Arul M Chinnaiyan, Deepak Nagrath, Mark M Zalupski, Vaibhav Sahai
Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: Pre-clinical evaluation and phase 1b multicenter clinical trial (BilT-04). Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Stephanie L Alden, Mir Lim, Chester Kao, Daniel H Shu, Amit G Singal, Anne M Noonan, Paige Griffith, Nilofer S Azad, Won Jin Ho, Ihab R Kamel, Mark Yarchoan, David Hsiehchen
Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma. Cancer research communications 3 (7) (2023)
Mir Lim, Maishara Muquith, Bernadette Miramontes, Magdalena Espinoza, David Hsiehchen
Treatment Beyond Progression After Anti-PD-1 Blockade in Hepatocellular Carcinoma. Cancer research communications 3 (9) (2023)
David Hsiehchen, Leslie Bucheit, Dong Yang, Muhammad Shaalan Beg, Mir Lim, Sunyoung S Lee, Pashtoon Murtaza Kasi, Ahmed O Kaseb, Hao Zhu
Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers. Nature communications 13 (1) (2022)
David Hsiehchen, Abdul Rafeh Naqash, Magdalena Espinoza, Mitchell S Von Itzstein, Alessio Cortellini, Biagio Ricciuti, Dwight H Owen, Mehak Laharwal, Yukihiro Toi, Michael Burke, Yang Xie, David E Gerber
Association between immune-related adverse event timing and treatment outcomes. Oncoimmunology 11 (1) (2022)
David Hsiehchen, Magdalena Espinoza, David E Gerber, Muhammad S Beg
Clinical and biological determinants of circulating tumor DNA detection and prognostication using a next-generation sequencing panel assay. Cancer biology & therapy 22 (7-9) (2021)